Bruce Cree
A5020903163- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Systemic Lupus Erythematosus Research
- Sphingolipid Metabolism and Signaling
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- Systemic Sclerosis and Related Diseases
- Autoimmune and Inflammatory Disorders Research
- Cytokine Signaling Pathways and Interactions
- Acute Lymphoblastic Leukemia research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Viral Infections and Immunology Research
- Gut microbiota and health
- Fungal Infections and Studies
- Phytochemistry and Biological Activities
- Liver Diseases and Immunity
- RNA regulation and disease
- Neuroinflammation and Neurodegeneration Mechanisms
- SARS-CoV-2 and COVID-19 Research
- Research on Leishmaniasis Studies
- Chronic Lymphocytic Leukemia Research
- Fungal Plant Pathogen Control
University of California, San Francisco
2016-2025
University of Basel
2021-2024
University of Pennsylvania
2018-2024
Center for Neurosciences
2020-2024
Heinrich Heine University Düsseldorf
2010-2024
St. Josef-Hospital
2014-2024
University of Nevada, Reno
2024
Renown Health
2024
Johns Hopkins University
2018-2024
Ruhr University Bochum
2014-2024
Multiple sclerosis has a clinically significant heritable component. We conducted genomewide association study to identify alleles associated with the risk of multiple sclerosis.We used DNA microarray technology common sequence variants in 931 family trios (consisting an affected child and both parents) tested them for association. For replication, we genotyped another 609 trios, 2322 case subjects, 789 control subjects genotyping data from two external sets. A joint analysis 12,360 was...
Significance We have experimentally investigated the immunoregulatory effects of human gut microbiota in multiple sclerosis (MS). identified specific bacteria that are associated with MS and demonstrated these regulate T lymphocyte-mediated adaptive immune responses contribute to proinflammatory environment vitro vivo. Thus, our results expand knowledge microbial regulation immunity may provide a basis for development microbiome-based therapeutics autoimmune diseases.
Eight patients with worsening neuromyelitis optica were treated rituximab to achieve B cell depletion. Treatment was well tolerated. Six of eight relapse free and median attack rate declined from 2.6 attacks/patient/year 0 (<i>p</i> = 0.0078). Seven experienced substantial recovery neurologic function over 1 year average follow-up. The pretreatment Expanded Disability Status Scale score 7.5, at follow-up examination 5.5 0.013).
Objective To develop recommendations for disease-modifying therapy (DMT) multiple sclerosis (MS). Methods A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine–compliant process to ensure transparency and patient engagement; modified Delphi consensus–based concerning starting, switching, stopping DMTs pertinent people with relapsing-remitting MS, secondary progressive primary clinically isolated syndromes...
Multiple sclerosis (MS), a chronic disorder of the central nervous system and common cause neurological disability in young adults, is characterized by moderate but complex risk heritability. Here we report results genome-wide association study performed 1000 prospective case series well-characterized individuals with MS group-matched controls using Sentrix® HumanHap550 BeadChip platform from Illumina. After stringent quality control data filtering, compared allele frequencies for 551 642...
Neuromyelitis optica (NMO) is an uncommon, life-threatening inflammatory demyelinating disorder. Recently, much has become known about its immunopathogenesis. However, optimal treatments, with expected outcomes, have not been established.To evaluate the use and efficacy of rituximab for treating NMO.Retrospective multicenter case series NMO patients treated rituximab.Seven tertiary medical centers in United States England.Twenty-five (including 2 children), 23 whom experienced relapses...
To characterize the accrual of long-term disability in a cohort actively treated multiple sclerosis (MS) patients and to assess whether clinical magnetic resonance imaging (MRI) data used trials have prognostic value.This is prospective study 517 managed MS enrolled at single center.More than 91% were retained, with ascertained up 10 years after baseline visit. At this last assessment, neurologic as measured by Expanded Disability Status Scale (EDSS) was stable or improved compared 41%...
Objective Rates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in actively treated patients compared natural history studies from the pretreatment era. Nonetheless, our recently reported prospective cohort, more than half with relapsing MS accumulated significant new disability by 10th year follow‐up. Notably, “no evidence disease activity” at 2 years did not predict long‐term stability. Here, we determined what extent clinical relapses...
Abstract Objective: Aquaporin 4 (AQP4)‐specific autoantibodies in neuromyelitis optica (NMO) are immunoglobulin (Ig)G1, a T cell‐dependent Ig subclass, indicating that AQP4‐specific cells participate NMO pathogenesis. Our goal was to identify and characterize patients healthy controls (HC). Methods: Peripheral blood from HC were examined for recognition of AQP4 production proinflammatory cytokines. Monocytes evaluated cell‐polarizing cytokines expression costimulatory molecules. Results:...
Significance Dimethyl fumarate (DMF) (BG-12, Tecfidera), a fumaric acid ester (FAE), is commonly prescribed oral therapy for multiple sclerosis (MS), CNS autoimmune inflammatory demyelinating disease that may result in sustained neurologic damage. It thought the benefit of DMF MS mediated through activation antioxidative transcription factor nuclear (erythroid-derived 2)-like 2 (Nrf2) pathway. However, role Nrf2 antiinflammatory effects has not been fully elucidated. Here, we investigated...
Background: ‘No evidence of disease activity’ (NEDA), defined as absence magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and disability progression (‘NEDA-3’), is used a comprehensive measure treatment response in relapsing multiple sclerosis (RMS), but weighted towards inflammatory activity. Accelerated brain volume loss (BVL) occurs RMS an objective worsening progression. Objective: To assess the contribution individual components NEDA-3 impact...
<h3>Background:</h3> Technological advancements in neuroimaging and the increased use of these diagnostic modalities are responsible for discovery incidentally identified anomalies within CNS. In addition to identification unanticipated brain MRI abnormalities suggestive demyelinating disease patients undergoing a medical reason other than evaluation multiple sclerosis (MS), asymptomatic spinal cord lesions periodically identified. <h3>Objective:</h3> To determine if associated with clinical...
In multiple sclerosis (MS) pathogenic B cells likely act on both sides of the blood-brain barrier (BBB). However, it is unclear whether antigen-experienced are shared between CNS and peripheral blood (PB) compartments. We applied deep repertoire sequencing IgG heavy chain variable region genes (IgG-VH) in paired cerebrospinal fluid PB samples from patients with MS other neurological diseases to identify related that common For first time our knowledge, we found a restricted pool clonally...